-
Mashup Score: 4
According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The phase 3 KEYLYNK-006 trial did not meet the primary end points of progression-free and overall survival in patients with metastatic nonsquamous non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2About the Continued Evaluation of MK-1084 for NSCLC and More - 6 day(s) ago
Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6FDA Accepts NDA for Ensartinib in Metastatic ALK-Positive NSCLC - 11 day(s) ago
The regulatory agency set an action date of December 28, 2024 for ensartinib as a treatment for those with ALK-positive non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
A cohort study for patients with non–small cell lung cancer found an overall survival benefit when targeted therapies were utilized.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Case 4: 71-Year-Old Diagnosed with Stage IIIA NSCLC Experiencing Pneumonitis After Chemo-IO Treatment - 13 day(s) ago
Dr. Gregory Gan presents Case 4, featuring a 71-year-old diagnosed with Stage IIIA NSCLC experiencing pneumonitis following Chemo-IO treatment, prompting a discussion with expert insight on the monitoring and management of this condition.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Newer TKIs Show Better Intracranial Responses in ROS1+ NSCLC - 14 day(s) ago
In the first article of a 2-part series, Christine Bestvina, MD, discussed the role of the newer tyrosine kinase inhibitor repotrectinib for patients with non–small cell lung cancer that is positive for a ROS1 mutation.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC - 14 day(s) ago
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Genomic discordances and heterogeneous mutational burden, PD-L1 expression and immune infiltrates of non-small cell lung cancer metastasis - 16 day(s) ago
Aims To investigate the genomic discordances and heterogeneous mutational burden, PD-L1 expression and immune cell (IC) infiltrates of non-small cell lung cancer (NSCLC) metastasis. Methods Surgical samples from 41 cases of NSCLC with metastatic tumours (MTs) and paired primary tumours (PTs) were collected. PD-L1 expression and ICs were quantified using image-based immunohistochemistry profiling. Whole exome sequencing was employed to explore discrepancies in genomic characteristics, tumour mutational burden (TMB) and tumour neoantigen burden (TNB) in 28 cases. Results Non-synonymous mutations in MTs were slightly more than in PTs, with only 42.34% of mutations shared between paired PTs and MTs. The heterogeneity of TMB showed no significant difference (p=0.785) between MTs and PTs, while TNB significantly increased in MTs (p=0.013). MTs generally exhibited a higher density of PD-L1+ cells and a higher tumour proportion score with a lower density of IC infiltrates. Subgroup analysis co
Source: jcp.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1
In this video, Dr. Leah Backhus, thoracic surgeon and professor of cardiothoracic surgery at Stanford Medicine, discusses the surgeon’s role in managing patients with resectable non-small cell lung cancer.
Source: www.sts.orgCategories: General Medicine News, Cardiac SurgeryTweet
The MARIPOSA trial of amivantamab + lazertinib vs standard-of-care osimertinib for the treatment of EGFR-mutated #NSCLC had promising results, showing the superiority of amivantamab/lazertinib over osimertinib. @AlexSpiraMDPhD @VCSpecialists https://t.co/IlolDnIS2W